Straits Times Index
3,187.66 +32.97 (+1.05%) S&P 500
5,014.62 -7.59 (-0.15%) Dow
37,802.03 +48.72 (+0.13%) Nasdaq
15,622.22 -61.15 (-0.39%) Bitcoin USD
63,299.30 +2,298.20 (+3.77%) CMC Crypto 200
885.54 0.00 (0.00%)
Valerio Therapeutics Société anonyme (C4X.F)
| Previous close | 0.1172 |
| Open | 0.1082 |
| Bid | 0.1186 x 460000 |
| Ask | 0.1206 x 450000 |
| Day's range | 0.1082 - 0.1082 |
| 52-week range | 0.0840 - 0.3320 |
| Volume | |
| Avg. volume | 300 |
| Market cap | 16.813M |
| Beta (5Y monthly) | 1.63 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Valerio Therapeutics Announces a Capital Reduction Motivated by Losses by Reducing the Nominal Value of the Company's Shares
PARIS, February 06, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announces a reduction of the par value of its shares.
- Business Wire
Half-Year Liquidity Contract Statement for Valerio Therapeutics
PARIS, January 31, 2024--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO)
- Business Wire
Valerio Therapeutics Reports its Half-Year 2023 Financial Results and Provides an Update on its Activities
PARIS, September 28, 2023--Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), hereafter "Valerio Therapeutics" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today reports its consolidated half-year financial results to June 30, 2023, and provides an update on its activities.
